Logo image of OCEA

OCEAN BIOMEDICAL INC (OCEA) Stock Fundamental Analysis

NASDAQ:OCEA - Nasdaq - US67644C1045 - Common Stock - Currency: USD

0.1  0 (-0.6%)

Premarket: 0.0993 0 (-0.7%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to OCEA. OCEA was compared to 571 industry peers in the Biotechnology industry. OCEA may be in some trouble as it scores bad on both profitability and health. OCEA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCEA has reported negative net income.
OCEA had a negative operating cash flow in the past year.
OCEA Yearly Net Income VS EBIT VS OCF VS FCFOCEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

OCEA has a Return On Assets of -2351.50%. This is amonst the worse of the industry: OCEA underperforms 99.64% of its industry peers.
Industry RankSector Rank
ROA -2351.5%
ROE N/A
ROIC N/A
ROA(3y)-694.07%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCEA Yearly ROA, ROE, ROICOCEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCEA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCEA Yearly Profit, Operating, Gross MarginsOCEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

OCEA has more shares outstanding than it did 1 year ago.
OCEA has a worse debt/assets ratio than last year.
OCEA Yearly Shares OutstandingOCEA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
OCEA Yearly Total Debt VS Total AssetsOCEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -293.13, we must say that OCEA is in the distress zone and has some risk of bankruptcy.
OCEA has a Altman-Z score of -293.13. This is amonst the worse of the industry: OCEA underperforms 98.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -293.13
ROIC/WACCN/A
WACCN/A
OCEA Yearly LT Debt VS Equity VS FCFOCEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.03 indicates that OCEA may have some problems paying its short term obligations.
With a Current ratio value of 0.03, OCEA is not doing good in the industry: 99.64% of the companies in the same industry are doing better.
A Quick Ratio of 0.03 indicates that OCEA may have some problems paying its short term obligations.
OCEA has a Quick ratio of 0.03. This is amonst the worse of the industry: OCEA underperforms 99.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
OCEA Yearly Current Assets VS Current LiabilitesOCEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

OCEA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.42%, which is quite impressive.
EPS 1Y (TTM)71.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OCEA Yearly Revenue VS EstimatesOCEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025
OCEA Yearly EPS VS EstimatesOCEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCEA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCEA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCEA Price Earnings VS Forward Price EarningsOCEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCEA Per share dataOCEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OCEA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCEAN BIOMEDICAL INC

NASDAQ:OCEA (2/28/2025, 8:05:58 PM)

Premarket: 0.0993 0 (-0.7%)

0.1

0 (-0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-04 2024-12-04
Earnings (Next)N/A N/A
Inst Owners2.83%
Inst Owner Change2.7%
Ins Owners0.06%
Ins Owner Change0%
Market Cap3.49M
Analysts82.86
Price TargetN/A
Short Float %1.21%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS-2.81
TBVpS-2.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2351.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-694.07%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -293.13
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.02%
EPS Next Y71.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y94.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-170.48%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-271.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-271.47%
OCF growth 3YN/A
OCF growth 5YN/A